title: Effects of rosuvastatin as an adjuvant treatment for deep vein thrombosis.
abstract: BACKGROUND
  Statins have been reported to help prevent the development and the recurrence of deep vein thrombosis (DVT). We conducted a prospective randomized clinical trial to compare the effects of rosuvastatin plus a low-molecular-weight heparin (LMWH), bemiparin, with conventional LMWH therapy in the treatment of DVT.
  
  
  METHODS
  In total, 234 patients were randomized into two groups, 116 in the LMWH group and 118 in the statin plus LMWH group. All patients underwent lower limb duplex ultrasound and analytic markers at diagnosis and three months of follow-up. The final analysis included 230 patients.
  
  
  RESULTS
  No significant differences were observed in D-dimer levels after three months of follow-up between patients treated with LMWH+rosuvastatin compared to the LMWH group (802.51 + 1062.20 vs. 996.25 + 1843.37, p = 0.897). The group of patients treated with statins displayed lower levels of CRP (4.17 + 4.27 vs. 22.39 + 97.48, p = 0.018) after three months of follow-up. The Villalta scale demonstrated significant differences between groups (3.45 + 6.03 vs. 7.79 + 5.58, p = 0.035). There was a significant decrease in PTS incidence (Villalta score> 5) in the rosuvastatin group (38.3 % vs. 48.5%, p = 0.019). There were no differences in EuroQol score between groups.
  
  
  CONCLUSIONS
  Adjuvant rosuvastatin treatment in patients diagnosed of DVT improve CRP levels and diminish PTS incidence.
authors.affiliation: 1 Valladolid University Hospital, Spain.
authors.forename: Enrique María
authors.initials: EM
authors.lastname: San Norberto
authors.affiliation: 1 Valladolid University Hospital, Spain.
authors.forename: María Victoria
authors.initials: MV
authors.lastname: Gastambide
authors.affiliation: 1 Valladolid University Hospital, Spain.
authors.forename: James Henry
authors.initials: JH
authors.lastname: Taylor
authors.affiliation: 2 University Hospital Rio Hortega, Spain.
authors.forename: Irene
authors.initials: I
authors.lastname: García-Saiz
authors.affiliation: 1 Valladolid University Hospital, Spain.
authors.forename: Carlos
authors.initials: C
authors.lastname: Vaquero
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D054070:Postthrombotic Syndrome / Q000517:prevention & control; D011446:Prospective Studies; D011788:Quality of Life; D000068718:Rosuvastatin Calcium / Q000009:adverse effects / Q000627:therapeutic use*; D013030:Spain; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D018616:Ultrasonography, Doppler, Duplex; D020246:Venous Thrombosis / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D006495:Heparin, Low-Molecular-Weight; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C036309:fibrin fragment D; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein
keywords: Randomized controlled trial; deep vein thrombosis; post-thrombotic syndrome; rosuvastatin; statin